一篇简明扼要的综述，探讨了一种治疗未治疗的局部晚期或转移性尿路上皮癌的新组合:enfortumab vedotin + pembrolizumab。

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-03-01 Epub Date: 2023-11-23 DOI:10.2217/fon-2023-0112

Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R Merchan, Rana R McKay, Daniel P Petrylak, Carolyn Sasse, Blanca Homet Moreno, Yao Yu, Anne-Sophie Carret, Jonathan E Rosenberg

{"title":"一篇简明扼要的综述，探讨了一种治疗未治疗的局部晚期或转移性尿路上皮癌的新组合:enfortumab vedotin + pembrolizumab。","authors":"Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R Merchan, Rana R McKay, Daniel P Petrylak, Carolyn Sasse, Blanca Homet Moreno, Yao Yu, Anne-Sophie Carret, Jonathan E Rosenberg","doi":"10.2217/fon-2023-0112","DOIUrl":null,"url":null,"abstract":"What is this summary about?: This summary provides the results of a study of two treatments for cancer, enfortumab vedotin and pembrolizumab, that were studied together against locally advanced or metastatic urothelial cancer (la/mUC), a cancer that occurs most commonly in the bladder.What were the results?: In the 45 patients studied, around 16% did have serious side effects, but most side effects were manageable. Twenty-four percent of patients, however, stopped the study treatment because of their side effects. Within about 2 months of starting treatment, most patients' (73%) tumors were smaller and stayed smaller, on average, for more than 2 years.What do the results mean?: The combination of enfortumab vedotin plus pembrolizumab is a new treatment option for patients with locally advanced or metastatic urothelial cancer when they cannot receive the typical treatment, cisplatin. Advanced or metastatic urothelial cancer is a type of cancer where the cancer has already spread outside of the bladder or urinary tract.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"351-360"},"PeriodicalIF":3.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988537/pdf/","citationCount":"0","resultStr":"{\"title\":\"A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.\",\"authors\":\"Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R Merchan, Rana R McKay, Daniel P Petrylak, Carolyn Sasse, Blanca Homet Moreno, Yao Yu, Anne-Sophie Carret, Jonathan E Rosenberg\",\"doi\":\"10.2217/fon-2023-0112\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"What is this summary about?: This summary provides the results of a study of two treatments for cancer, enfortumab vedotin and pembrolizumab, that were studied together against locally advanced or metastatic urothelial cancer (la/mUC), a cancer that occurs most commonly in the bladder.What were the results?: In the 45 patients studied, around 16% did have serious side effects, but most side effects were manageable. Twenty-four percent of patients, however, stopped the study treatment because of their side effects. Within about 2 months of starting treatment, most patients' (73%) tumors were smaller and stayed smaller, on average, for more than 2 years.What do the results mean?: The combination of enfortumab vedotin plus pembrolizumab is a new treatment option for patients with locally advanced or metastatic urothelial cancer when they cannot receive the typical treatment, cisplatin. Advanced or metastatic urothelial cancer is a type of cancer where the cancer has already spread outside of the bladder or urinary tract.\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"351-360\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988537/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/fon-2023-0112\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fon-2023-0112","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

这个总结是关于什么的?本综述提供了两种治疗癌症的研究结果，enfortumab vedotin和pembrolizumab，这两种治疗方法一起研究了局部晚期或转移性尿路上皮癌(la/mUC)，这是一种最常见于膀胱的癌症。结果如何?在研究的45名患者中，大约16%的患者确实有严重的副作用，但大多数副作用是可控的。然而，24%的患者因为副作用而停止了研究治疗。在开始治疗约2个月内，大多数患者(73%)的肿瘤变小，并且平均持续时间超过2年。这些结果意味着什么?对于局部晚期或转移性尿路上皮癌患者，当他们不能接受典型的顺铂治疗时，联合使用enfortumab vedotin和pembrolizumab是一种新的治疗选择。晚期或转移性尿路上皮癌是癌症已经扩散到膀胱或尿道外的一种癌症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.

What is this summary about?: This summary provides the results of a study of two treatments for cancer, enfortumab vedotin and pembrolizumab, that were studied together against locally advanced or metastatic urothelial cancer (la/mUC), a cancer that occurs most commonly in the bladder.

What were the results?: In the 45 patients studied, around 16% did have serious side effects, but most side effects were manageable. Twenty-four percent of patients, however, stopped the study treatment because of their side effects. Within about 2 months of starting treatment, most patients' (73%) tumors were smaller and stayed smaller, on average, for more than 2 years.

What do the results mean?: The combination of enfortumab vedotin plus pembrolizumab is a new treatment option for patients with locally advanced or metastatic urothelial cancer when they cannot receive the typical treatment, cisplatin. Advanced or metastatic urothelial cancer is a type of cancer where the cancer has already spread outside of the bladder or urinary tract.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.